PETACH TIKVA, Israel (BUSINESS WIRE) Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology
‘Reassuring’ research on those who got two vaccine shots bodes well for oncology patients now receiving boosters, say doctors from Rabin Medical Center
Beilinson Hospital in Petah Tikva.
Prof. Salomon Stemmer, Director of the Oncology Research Unit at Davidoff Center, Beilinson Hospital: “We found that there is a high enough level of antibodies to provide full protection for 90% of oncology patients undergoing active anti-cancer treatment.”
Israeli researchers have been examining the relationship between the COVID-19 vaccine (messenger RNA SARS-CoV-2) and patients undergoing treatment for various types of cancer.
The findings suggest that patients with cancer who are receiving active treatment and are at higher risk for severe COVID-19 disease, respond well to RNA SARS-CoV-2 vaccines, and that vaccination of these patients should be seriously considered. More than 90% of oncology patients have responded well to the vaccine.